Результаты поиска

Serum Free Light-Chain Ratio at Diagnosis Is Associated with Early Renal Damage in Multiple Myeloma: A Case Series Real-World Study.

The serum free light-chain (FLC) ratio is a sensitive tool for the differential diagnosis of plasma cell disorders and is biomarker of multiple myeloma (MM) progression from premalignant conditions. Here, we investigate the potential role of FLC ratio at diagnosis in identifying early renal damage in MM patients and other correlations with clinical, laboratory, and molecular findings. A total of 34 MM patients who had undergone autologous stem cell transplantation were included in this retrospective case series study, and FLC quantification was performed with nephelometric assays. In our study

Role of zoledronic acid in the prevention and treatment of osteoporosis.

Taken once a year, intravenous zoledronic acid (Zol) (Reclast® or Aclasta®) is a third-generation nitrogen-containing bisphosphonate that is effective compared with placebo in reducing the risk of fractures in patients with postmenopausal osteoporosis and recent low-trauma hip fracture. In glucocorticoid-induced osteoporosis, there is no significant difference between Zol and risedronate for new fractures. Improvements in bone mineral density and early reduction of bone remodeling markers are observed in postmenopausal osteoporosis, recent low-trauma hip fracture, and glucocorticoid-induced os

Safety and Feasibility of Steerable Radiofrequency Ablation in Combination with Cementoplasty for the Treatment of Large Extraspinal Bone Metastases.

Background: Radiofrequency ablation (RFA) and cementoplasty, individually and in concert, has been adopted as palliative interventional strategies to reduce pain caused by bone metastases and prevent skeletal related events. We aim to evaluate the feasibility and safety of a steerable RFA device with an articulating bipolar extensible electrode for the treatment of extraspinal bone metastases. Methods: All data were retrospectively reviewed. All the ablation procedures were performed using a steerable RFA device (STAR, Merit Medical Systems, Inc., South Jordan, UT, USA). The pain was assessed

Symptom burden in transplant ineligible patients with newly diagnosed multiple myeloma: a population-based cohort study.

Not available.

Real-world outcomes for multiple myeloma patients after apheresis for planned chimeric antigen receptor T-cell therapy.

BACKGROUND: Chimeric antigen receptor T-cell (CAR-T) therapy is highly active in relapsed/refractory multiple myeloma (RRMM), but manufacturing creates an obligatory waiting period between apheresis and infusion. Patients may deteriorate, progress or die during this window. Analyses that begin follow-up at infusion exclude these patients entirely and cannot describe the experience of all patients who enter the CAR-T pathway. AIM: To describe, in an intention-to-collect fashion, the outcomes of all RRMM patients who underwent T-cell apheresis for planned CAR-T therapy; to characterise the apher

Acceptability and Effectiveness of a Fully Web-Based Nutrition and Exercise Program for Individuals With Chronic Disease During COVID-19: Randomized Controlled Trial.

BackgroundIn-person nutrition and exercise interventions improve physical function in chronic diseases, yet the acceptability and effectiveness of web-based delivery, especially with different levels of personnel support, require further investigation.ObjectiveThis study aims to evaluate a web-based nutrition and exercise intervention delivered entirely digitally from recruitment to trial completion.MethodsA randomized controlled trial was conducted using the Heal-Me version 1 platform across 2 levels of personnel support (Light and Intensive). Eligible adults with a history of cancer, chronic

Совпадение в полном тексте источника
… Thus, with a 2-sided α=.05 (.0167 adjusted for multiple comparisons) and β=.20 (80% power), 60 participants per group (180 in total) were estimated to be required to determine a statistically significant difference for a moderate (0.6) Cohen d effect size (minimal clinically important difference of 9 … The normative score of the LEFS is 63 for both male and female individuals aged 60-64 years, with a maximum value of 80 and a minimal clinically important difference of 9 points [ 28 ]. …

Революция онкологии: роль искусственного интеллекта (AI) в качестве антителного дизайна и средств оптимизации.

Антитела играют решающую роль в защите человеческого тела от болезней, включая такие опасные для жизни заболевания, как рак. Они оказывают посреднические услуги в связи с иммунной реакцией на иностранные антигены и, в некоторых случаях, на самоантигены. С течением времени антителные технологии эволюционировали от моноклонных антител (mAbs) до химерика антигенных рецепторов Т (клеток CAR-T), оказывая значительное влияние на биотехнологию, диагностику и лечение. Хотя эти достижения способствовали активизации терапевтического вмешательства, интеграция искусственного интеллекта (АИ) революционизир

Изучение сегментации мозга с участием многих папологов: от глубокого анализа знаний на основе физического объема до компонентов.

Обнаружение и сегментация аномалий мозга с использованием магнитного резонансного воображения (MRI) является важной задачей, которая в настоящее время четко закрепляется как на уровне исследований, так и на уровне клинического производства роль алгоритмов АИ как вспомогательных инструментов. Хотя эффективность современных моделей возрастает и во многих случаях достигает уровней точности радиологов и других экспертов, все еще необходимо провести много исследований по вопросу о направлении углубленной и транспарентной оценки правильных результатов и неудач, особенно в том, что касается важных ас

Abstracts of the ICARE 2024 78th SIAARTI National Congress

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Outcomes and Complications of Surgery for Symptomatic Spinal Metastases; a Comparison Between Patients Aged ≥ 70 and <70.

Study designRetrospective cohort study.ObjectivePhysicians may be deterred from operating on elderly patients due to fears of poorer outcomes and complications. We aimed to compare the outcomes of surgical treatment of spinal metastases patients aged ≥70-yrs and Materials and methodsThis is a retrospective study of patients surgically treated for metastatic epidural spinal cord compression and spinal instability between January-2005 to December-2021. Follow-up was till death or minimum 1-year post-surgery. Outcomes included post-operative neurological status, ambulatory status, medical and sur

Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO.

BackgroundPatients' experience of symptoms often goes undetected during consultation in an outpatient clinic, and the use of a patient-reported outcome measure (PRO) in such a setting could be useful to aid treatment decision-making. A new PRO measure, the HM-PRO (Hematological Malignancy Specific Patient-Reported Outcome Measure) has been recently developed to evaluate hematological malignancy (HM) patients' health-related quality of life (HRQoL) and their symptom experience in daily clinical practice as well as in research. The objectives of the study were to assess: the internal consistency

Совпадение в полном тексте источника
… Responsiveness and the Minimal Clinically Important Difference for HM-PRO in Patients with Hematological Malignancies. Blood 132, 2294. 10.1182/blood-2018-99-117094 Goswami P., Oliva E. N., Ionova T., Salek S. (2018. b). …

Свойства измерений и их применение WHODAS 2.0 в многоразовом склерозе: систематический обзор.

Фон/задачи: Множественный склероз (МС) влияет на моторное, когнитивное, психологическое и социальное функционирование, которое не в полной мере фиксируется на основе нарушений. В ходе этого систематического обзора была проведена оценка свойств измерений и их применения в соответствии с графиком Всемирной организации здравоохранения по оценке инвалидности (WHODAS) 2.0 для взрослых с МЗ в исследовательских и клинических контекстах. Методы: с момента создания библиотеки Пубмед/МЕДЛИН, Эмбазы, Скопуса, Сети науки и Кокрана до 25 мая 2026 года был проведен обыск. В ходе соответствующих экспертных и

Совпадение в полном тексте источника
… Moderate certainty for measurement properties means reasonable confidence that selected WHODAS total-score implementations measure functioning consistently in MS; it does not demonstrate diagnostic accuracy, a minimal clinically important difference, predictive validity, or effectiveness as an intervention …

The burden of amyloid light chain amyloidosis on health-related quality of life.

BackgroundLight chain (AL) amyloidosis is a rare disease characterized by misfolded amyloid protein deposits in tissues and vital organs, and little is known about the burden of AL amyloidosis on health-related quality of life. This study aimed to quantify the burden of AL amyloidosis in terms of health-related quality of life in a diverse, community-based sample of AL amyloidosis patients.ResultsThe SF-36v2® Health Survey (SF-36v2), a widely used generic measure of health-related quality of life (using physical and mental summary scales and subscales assessing eight aspects of functioning and

Совпадение в полном тексте источника
… Previously reported minimal clinically important differences (MCIDs) for each of the eight scales, PCS, and MCS were used to interpret whether statistically significant differences were also clinically meaningful [ 15 ]. … Abbreviations Amyloid light chain Bodily pain European medicines agency United States food and drug administration General educational development General health General population Hematologic response Health-related quality of life Informed consent form Minimal clinically important difference …

Past, Present, and a Glance into the Future of Multiple Myeloma Treatment.

Multiple myeloma (MM) is a challenging hematological cancer which typically grows in bone marrow. MM accounts for 10% of hematological malignancies and 1.8% of cancers. The recent treatment strategies have significantly improved progression-free survival for MM patients in the last decade; however, a relapse for most MM patients is inevitable. In this review we discuss current treatment, important pathways for proliferation, survival, immune suppression, and resistance that could be targeted for future treatments.

Therapeutic Potential of CAR-CIK Cells in Acute Leukemia Relapsed Post Allogeneic Stem Cell Transplantation.

Adoptive cellular therapy with donor-derived T cells has always been an attractive strategy after allogeneic hematopoietic stem cell transplantation (allo-HSCT) to reduce the risk of relapse in acute myeloid and lymphoid leukemias. Donor lymphocyte infusion (DLI) is still the best-established option, especially in the preemptive phase when measurable residual disease (MRD) becomes positive and in the prophylactic setting-when MRD is not detectable. However, the clinical benefit of DLI is counterbalanced by the possible onset of graft-versus-host disease (GvHD), which continues to restrict its

A Review of Repurposed Cancer Drugs in Clinical Trials for Potential Treatment of COVID-19.

The pandemic of the coronavirus disease 2019 (COVID-19) represents an unprecedented challenge to identify effective drugs for prevention and treatment. While the world's attention is focused on news of COVID-19 vaccine updates, clinical management still requires improvement. Due to the similarity of cancer-induced inflammation, immune dysfunction, and coagulopathy to COVID-19, anticancer drugs, such as Interferon, Pembrolizumab or Bicalutamide, are already being tested in clinical trials for repurposing, alone or in combination. Given the rapid pace of scientific discovery and clinical data ge

Evolving role of biomaterials in diagnostic and therapeutic radiation oncology.

Radiation therapy to treat cancer has evolved significantly since the discovery of x-rays. Yet, radiation therapy still has room for improvement in reducing side effects and improving control of cancer. Safer and more effective delivery of radiation has led us to novel techniques and use of biomaterials. Biomaterials in combination with radiation and chemotherapy have started to appear in pre-clinical explorations and clinical applications, with many more on the horizon. Biomaterials have revolutionized the field of diagnostic imaging, and now are being cultivated into the field of theranostic

Стойкость к Ocrelizumab по сравнению с другими лекарственными препаратами для нескольких склерозов: результаты немецкого регистра нейротрансфер данных.

ВВЕДЕНИЕ: Устойчивость лечения имеет решающее значение для получения полного терапевтического пособия и может указывать на благоприятные результаты. В рамках этого исследования изучался вопрос о стойкости в реальном мире к воздействию острелизумаба (ОКР) в сравнении с другими методами лечения, позволяющими видоизменить заболевания (ДМТ), и его связь с результатами повторного выброса нескольких склерозов (РРМС) с использованием данных немецкого реестра нейротрансданных (НТД). МЕТОДЫ: Этот ретроспективный когортный анализ охватывал амбулаторных больных, которые с января инициировали ДМТ 2014 и а

Integrating CRISPR/Cas technology with clinical trials: Principles, progress and challenges.

CRISPR represent a groundbreaking genome-editing technology that has revolutionized genetic modification. This innovative tool offers an unparalleled revolution in the future treatment of genetic disorders, neurological diseases, infectious diseases and cancer. Despite the rapid expansion of CRISPR applications, its clinical use in humans is still relatively limited, with only 69 active clinical trials and 6 completed studies reported so far. This review examined current clinical trials and their processes in addressing various diseases via the CRISPR/Cas system. While earlier literatures have

Efficacy and safety of daratumumab in the treatment of relapsed/refractory multiple myeloma: A meta-analysis of randomized controlled trials.

BackgroundDaratumumab as a monoclonal antibody has shown promising results in the treatment of relapsed/refractory multiple myeloma (RRMM). However, the efficacy and safety of daratumumab-based regimens compared to control regimens have not been fully established.MethodsThe search was conducted using electronic databases (PubMed, Web of Science, Embase, and Cochrane Central Register of Controlled Trials databases) up to December 2022. We conducted a meta-analysis of randomized controlled trials that evaluated the efficacy and safety of daratumumab in the treatment of RRMM. Data were extracted